136 related articles for article (PubMed ID: 36434146)
1. Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.
Basu M; Mukhopadhyay D; Chakraborty B; Ghosh S; Pal DK; Ghosh A; Panda CK
Mol Cell Biochem; 2023 Jul; 478(7):1599-1610. PubMed ID: 36434146
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.
Peng M; Xie J; Ucher A; Stavnezer J; Cantor SB
EMBO J; 2014 Aug; 33(15):1698-712. PubMed ID: 24966277
[TBL] [Abstract][Full Text] [Related]
3. Functional and physical interaction between the mismatch repair and FA-BRCA pathways.
Williams SA; Wilson JB; Clark AP; Mitson-Salazar A; Tomashevski A; Ananth S; Glazer PM; Semmes OJ; Bale AE; Jones NJ; Kupfer GM
Hum Mol Genet; 2011 Nov; 20(22):4395-410. PubMed ID: 21865299
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
5. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
6. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
7. Role of MLH1 and MSH2 deficiency in the development of tumorigenesis and chemo-tolerance of cervical Carcinoma: Clinical implications.
Dutta P; Pal D; Roy A; Mandal RK; Panda CK
Gene; 2023 Dec; 888():147746. PubMed ID: 37657688
[TBL] [Abstract][Full Text] [Related]
8. Embryonic lethality after combined inactivation of Fancd2 and Mlh1 in mice.
van de Vrugt HJ; Eaton L; Hanlon Newell A; Al-Dhalimy M; Liskay RM; Olson SB; Grompe M
Cancer Res; 2009 Dec; 69(24):9431-8. PubMed ID: 19934329
[TBL] [Abstract][Full Text] [Related]
9. Mlh1 interacts with both Msh2 and Msh6 for recruitment during mismatch repair.
DuPrie ML; Palacio T; Calil FA; Kolodner RD; Putnam CD
DNA Repair (Amst); 2022 Nov; 119():103405. PubMed ID: 36122480
[TBL] [Abstract][Full Text] [Related]
10. Expression of mismatch repair proteins in urothelial carcinoma of the urinary bladder.
Mohamedali R; Adhya AK; Mandal S; Mitra S
Indian J Cancer; 2022; 59(2):279-281. PubMed ID: 35946190
[TBL] [Abstract][Full Text] [Related]
11. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
13. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
[TBL] [Abstract][Full Text] [Related]
14. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
15. The properties of Msh2-Msh6 ATP binding mutants suggest a signal amplification mechanism in DNA mismatch repair.
Graham WJ; Putnam CD; Kolodner RD
J Biol Chem; 2018 Nov; 293(47):18055-18070. PubMed ID: 30237169
[TBL] [Abstract][Full Text] [Related]
16. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
17. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of mutS homolog 2 and mutL homolog 1 affects overall survival in laryngeal squamous cell carcinoma patients: Investigation into a potential cause.
Gong HL; Shi Y; Shi Y; Wu CP; Cao PY; Zhou L; Xu C
Oncol Rep; 2013 Sep; 30(3):1371-9. PubMed ID: 23787767
[TBL] [Abstract][Full Text] [Related]
19. Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients.
Perrett CM; Harwood CA; McGregor JM; Warwick J; Cerio R; Karran P
Br J Dermatol; 2010 Apr; 162(4):732-42. PubMed ID: 19818066
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma.
Uehara H; Miyamoto M; Kato K; Cho Y; Kurokawa T; Murakami S; Fukunaga A; Ebihara Y; Kaneko H; Hashimoto H; Murakami Y; Shichinohe T; Kawarada Y; Itoh T; Okushiba S; Kondo S; Katoh H
J Surg Oncol; 2005 Nov; 92(2):109-15. PubMed ID: 16231369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
